Su A Lee

Title: Innovations of Su A Lee in Cancer Therapy

Introduction

Su A Lee is an accomplished inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biomedical research, particularly in the development of therapeutic agents for cancer treatment. His innovative work focuses on bispecific antibodies, which have the potential to revolutionize cancer therapy.

Latest Patents

Su A Lee holds a patent for a bispecific antibody specifically binding to GPNMB and CD3. This antibody demonstrates high affinity and specificity to both CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B). The patent outlines the use of this bispecific antibody to induce death in cancer cells that express GPNMB while inhibiting their proliferation. This innovation positions the bispecific antibody as an effective therapeutic agent for cancers that express GPNMB.

Career Highlights

Throughout his career, Su A Lee has worked with notable organizations, including the Green Cross Corporation and Mogam Institute for Biomedical Research. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

Su A Lee has collaborated with several professionals in his field, including Jae Chan Park and Eun Jung Song. These collaborations have fostered a productive environment for research and innovation in cancer treatment.

Conclusion

Su A Lee's work in developing bispecific antibodies represents a significant advancement in cancer therapy. His innovative approach has the potential to improve treatment outcomes for patients with cancers expressing GPNMB.